-
New Forum Software Installed (Still a few issues but reopening the forum) More details.
respiratory syncytial virus
-
GSK’s older adult … vaccine candidate shows 94.1% reduction in severe RSV disease and overall vaccine efficacy of 82.6%
GSK’s older adult respiratory syncytial virus (RSV) vaccine candidate shows 94.1% reduction in severe RSV disease and overall vaccine efficacy of 82.6% in pivotal trial Data to be presented at IDWeek 2022 showed overall vaccine efficacy against RSV-lower respiratory tract disease (LRTD) in...- cassava7
- Thread
- respiratory syncytial virus rsv vaccine
- Replies: 0
- Forum: Other health news and research